AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products include Crestor for dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium to treat acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. As of December 31, 2014, it had 133 pipeline projects. The company markets its products through distributors and local representative offices. It also engages in the insurance and reinsurance underwriting business. The company has a strategic collaboration with Isis Pharmaceuticals, Inc.; collaboration agreements with Celgene Corporation, Immunocore Limited, Kyowa Hakko Kirin Co., Ltd., Advaxis Inc., Pharmacyclics Inc., The University of Manchester, and Janssen Research & Development, LLC.; and a development and commercialization agreement with Allergan plc. It also has a license from Heptares Therapeutics Ltd. to develop, manufacture, and commercialize the adenosine A2A receptor antagonist, HTL-1071. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.